GW Pharmaceuticals PLC- (GWPH) Earns Outperform Rating from Analysts at Leerink Swann
Leerink Swann began coverage on shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) in a report issued on Monday morning, MarketBeat.com reports. The brokerage issued an outperform rating and a $185.00 price objective on the biopharmaceutical company’s stock. Leerink Swann also issued estimates for GW Pharmaceuticals PLC-‘s Q4 2018 earnings at ($2.70) EPS, Q1 2019 earnings at ($2.40) EPS, Q2 2019 earnings at ($2.43) EPS, Q3 2019 earnings at ($2.03) EPS, Q4 2019 earnings at ($1.68) EPS and Q1 2020 earnings at ($1.31) EPS.
Several other equities analysts have also commented on the company. Morgan Stanley set a $227.00 price target on GW Pharmaceuticals PLC- and gave the company a buy rating in a research note on Thursday, October 11th. Zacks Investment Research downgraded GW Pharmaceuticals PLC- from a buy rating to a hold rating in a report on Friday, August 10th. BidaskClub downgraded GW Pharmaceuticals PLC- from a hold rating to a sell rating in a report on Wednesday, August 1st. Stifel Nicolaus started coverage on GW Pharmaceuticals PLC- in a report on Tuesday, August 14th. They issued a buy rating and a $181.00 price objective on the stock. Finally, ValuEngine downgraded GW Pharmaceuticals PLC- from a buy rating to a hold rating in a report on Thursday, August 2nd. One research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. GW Pharmaceuticals PLC- presently has a consensus rating of Buy and a consensus target price of $187.63.
Shares of GW Pharmaceuticals PLC- stock traded down $3.10 during trading hours on Monday, hitting $126.15. The company’s stock had a trading volume of 96,759 shares, compared to its average volume of 453,805. GW Pharmaceuticals PLC- has a twelve month low of $105.12 and a twelve month high of $179.65. The firm has a market cap of $4.05 billion, a PE ratio of -18.15 and a beta of 2.25. The company has a quick ratio of 8.21, a current ratio of 8.67 and a debt-to-equity ratio of 0.01.
GW Pharmaceuticals PLC- Company Profile
GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development.
Featured Article: How Buying a Call Option Works
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.